Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from PYC Therapeutics Limited ( (AU:PYC) ).
PYC Therapeutics Limited has notified the market that it will issue 2,000,000 unlisted options as unquoted equity securities, effective 23 December 2025. The creation of this new class of unlisted options indicates the company is using equity-based instruments, likely for capital management or incentive purposes, which may affect ownership structure and align stakeholders’ interests with the company’s longer-term performance.
The most recent analyst rating on (AU:PYC) stock is a Buy with a A$2.85 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
More about PYC Therapeutics Limited
PYC Therapeutics Limited is an Australia-listed biotechnology company (ASX: PYC) focused on developing therapeutic products, operating within the life sciences sector and funded in part through equity issuances on the ASX capital markets.
Average Trading Volume: 476,660
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$874.9M
For an in-depth examination of PYC stock, go to TipRanks’ Overview page.